Aberdeen Group
PCRX icon

Aberdeen Group’s Pacira BioSciences PCRX Stock Holding History

Aberdeen Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-609,351
Closed -$17.4M – 955
2024
Q2 		$17.4M Buy
609,351
+64,433
+12% +$1.83M 0.03% 407
2024
Q1 		$15.9M Buy
544,918
+96,227
+21% +$2.96M 0.03% 460
2023
Q4 		$15.1M Buy
448,691
+56,081
+14% +$1.64M 0.03% 456
2023
Q3 		$12M Sell
392,610
-83,811
-18% -$3.02M 0.03% 414
2023
Q2 		$19.1M Buy
+476,421
New +$19.7M 0.04% 352

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Aberdeen Group's PCRX Position: Q3 2024 in Review

Aberdeen Group sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 609,351 shares — an estimated $17.4M sold.

Aberdeen Group first reported a position in PCRX in Q2 2023 and held it in 5 quarters. The position peaked at $19.1M in Q2 2023. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Aberdeen Group reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 609,351 Pacira BioSciences shares in Q3 2024, an estimated $17.4M.
  • Aberdeen Group first reported a position in Pacira BioSciences in Q2 2023 and held it in 5 quarters.
  • Aberdeen Group's Pacira BioSciences position peaked at $19.1M in Q2 2023.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.